Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance: author's response

Lise Goltermann; Helle Krogh Johansen; Søren Molin; Ruggero La Rosa

doi:10.1016/j.cmi.2022.09.010

Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance: author's response

Lise Goltermann, Helle Krogh Johansen, Søren Molin, Ruggero La Rosa^*

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

1 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Clinical Microbiology and Infection
Vol/bind	28
Udgave nummer	12
Sider (fra-til)	1667-1668
Antal sider	2
ISSN	1198-743X
DOI	https://doi.org/10.1016/j.cmi.2022.09.010
Status	Udgivet - 2022

Bibliografisk note

Funding Information:
The authors declare that they have no conflicts of interest. This research was funded by the ‘ Cystic Fibrosis Foundation ’ (grant MOLIN18G0 ), the ‘ Cystic Fibrosis Trust ’ (grant Strategic Research Centre Award—2019—SRC 017) by the ‘ Novo Nordisk Foundation ’ (grants NNF10CC1016517 and NNF20CC0035580 ), and by the ‘ Independent Research Fund Denmark/Natural Sciences ’ (grant 9040-00106B ). H.K.J. was supported by the ‘ Novo Nordisk Foundation ’ (grants NNF12OC1015920 , NNF18OC0052776 , and NNF19OC0056411 ) and by the ‘ Independent Research Fund Denmark/Medical and Health Sciences ’ (grant DFF-9039-00037A ).

Adgang til dokumentet

10.1016/j.cmi.2022.09.010

Citationsformater

Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance : author's response. / Goltermann, Lise; Johansen, Helle Krogh; Molin, Søren; La Rosa, Ruggero.

I: Clinical Microbiology and Infection, Bind 28, Nr. 12, 2022, s. 1667-1668.

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

@article{9080f311b6c7433a9e7f0381ec72e1c8,

title = "Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance: author's response",

author = "Lise Goltermann and Johansen, {Helle Krogh} and S{\o}ren Molin and {La Rosa}, Ruggero",

note = "Funding Information: The authors declare that they have no conflicts of interest. This research was funded by the {\textquoteleft} Cystic Fibrosis Foundation {\textquoteright} (grant MOLIN18G0 ), the {\textquoteleft} Cystic Fibrosis Trust {\textquoteright} (grant Strategic Research Centre Award—2019—SRC 017) by the {\textquoteleft} Novo Nordisk Foundation {\textquoteright} (grants NNF10CC1016517 and NNF20CC0035580 ), and by the {\textquoteleft} Independent Research Fund Denmark/Natural Sciences {\textquoteright} (grant 9040-00106B ). H.K.J. was supported by the {\textquoteleft} Novo Nordisk Foundation {\textquoteright} (grants NNF12OC1015920 , NNF18OC0052776 , and NNF19OC0056411 ) and by the {\textquoteleft} Independent Research Fund Denmark/Medical and Health Sciences {\textquoteright} (grant DFF-9039-00037A ).",

year = "2022",

doi = "10.1016/j.cmi.2022.09.010",

language = "English",

volume = "28",

pages = "1667--1668",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier",

number = "12",

}

TY - JOUR

T1 - Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance

T2 - author's response

AU - Goltermann, Lise

AU - Johansen, Helle Krogh

AU - Molin, Søren

AU - La Rosa, Ruggero

N1 - Funding Information: The authors declare that they have no conflicts of interest. This research was funded by the ‘ Cystic Fibrosis Foundation ’ (grant MOLIN18G0 ), the ‘ Cystic Fibrosis Trust ’ (grant Strategic Research Centre Award—2019—SRC 017) by the ‘ Novo Nordisk Foundation ’ (grants NNF10CC1016517 and NNF20CC0035580 ), and by the ‘ Independent Research Fund Denmark/Natural Sciences ’ (grant 9040-00106B ). H.K.J. was supported by the ‘ Novo Nordisk Foundation ’ (grants NNF12OC1015920 , NNF18OC0052776 , and NNF19OC0056411 ) and by the ‘ Independent Research Fund Denmark/Medical and Health Sciences ’ (grant DFF-9039-00037A ).

PY - 2022

Y1 - 2022

U2 - 10.1016/j.cmi.2022.09.010

DO - 10.1016/j.cmi.2022.09.010

M3 - Comment/debate

C2 - 36150672

AN - SCOPUS:85142222817

VL - 28

SP - 1667

EP - 1668

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 12

ER -